<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00634803</url>
  </required_header>
  <id_info>
    <org_study_id>0608001776</org_study_id>
    <secondary_id>1R01DA024695-01A2</secondary_id>
    <nct_id>NCT00634803</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Integrated Treatment for Pain and Opioid Dependence</brief_title>
  <acronym>POD</acronym>
  <official_title>Clinical Trial of Integrated Treatment for Pain and Opioid Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to develop an effective psychotherapy for chronic pain and opioid&#xD;
      dependence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to develop a novel manualized intervention using tailored&#xD;
      cognitive-behavioral treatment (CBT) and buprenorphine medication to effectively treat the&#xD;
      co-occurring disorders of non-malignant pain and opioid dependence (POD).&#xD;
&#xD;
      Specific Aims:&#xD;
&#xD;
        1. To conduct a pre-pilot phase with 16 patients with POD receiving buprenorphine&#xD;
           maintenance treatment (BMT). In the pre-pilot phase, we will also explore the effects of&#xD;
           different daily buprenorphine dosages on pain and opiate use.&#xD;
&#xD;
        2. To conduct a pilot randomized, clinical trial to obtain data regarding the feasibility,&#xD;
           acceptability and efficacy (compared to Physician Management(PM) only) of manual-guided&#xD;
           CBT or Educational Counseling (EC) for patients with POD treated with BMT (N=75).&#xD;
&#xD;
      The secondary outcomes: Development of a Treatment Manual and Development and Modification of&#xD;
      Initial Therapy Training and Process Rating Measures were process measures and not been to be&#xD;
      included as measures associated with RCT. These outcomes were removed when the RCT results&#xD;
      were entered. In addition, outcomes were renamed for clarification.&#xD;
&#xD;
      At results entry, the timeframe (16 weeks) was also corrected to account for the actual&#xD;
      timeframe used for analysis in the study. The 16-week study period listed in the protocol&#xD;
      included a 2-week buprenorphine induction period (before randomization) and up to a 2-week&#xD;
      post-conclusion of the clinical trial continuation on buprenorphine and referral to&#xD;
      continuing treatment. In prior studies with buprenorphine, the study team had observed an&#xD;
      artificially high attrition during the last 2 weeks of the planned study protocol, when&#xD;
      participants were attempting to transition to available clinical treatments outside of the&#xD;
      study. Consequently, as per the original study protocol for this study, the plan was to&#xD;
      analyze intake and induction data (as baseline data) and then the data from the first&#xD;
      12-weeks post-randomization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity</measure>
    <time_frame>3 months</time_frame>
    <description>Pain intensity comprises the average of 4 items related to current pain and past-week average pain, pain at its worst, and pain at its least. Pain intensity is scored on 0-10 scale (average score ranges from 0-10), where higher scores indicate higher pain intensity.Originally labeled as Pain Reduction at 16 weeks- 3 months was the correct timeframe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Opioid-negative Urine Toxicology Tests</measure>
    <time_frame>3 Months</time_frame>
    <description>Reduced illicit opioid use is defined as the number of documented opioid negative urine tests in each of the time periods.This measures the reduction in illicit opioid use - more opioid-negative tests means greater reductions in illicit opioid use. The highest possible score is 4- which would indicate 4 negative urine tests during the assessment period. Originally titled &quot;Reduced illicit opioid use&quot; and the timeframe was listed as 16 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Interference</measure>
    <time_frame>3 Months</time_frame>
    <description>Pain interference comprises the average of 7 items related to past-week pain-related interference in general activity, walking, work, mood, enjoyment of life, relations with others, and sleep. Each item is scored on a 0-10 scale (averaged 0-10), where higher scores indicate higher pain interference.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Opiate Dependence</condition>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>CBT for POD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Integrated cognitive behavioral therapy for chronic pain and opioid dependence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Educational Counseling for POD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Educational Counseling is a didactic, lecture-discussion format to supplement the information and advice provided by physicians in physician management (PM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Physician Management</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PM is a relatively brief intervention that approximates the medically focused advice and brief counseling about medical issues that is typically provided by physicians to patients with chronic pain or other chronic medical conditions, such as diabetes or asthma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CBT</intervention_name>
    <description>Cognitive behavioral therapy</description>
    <arm_group_label>CBT for POD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>buprenorphine/naloxone</description>
    <arm_group_label>CBT for POD</arm_group_label>
    <arm_group_label>Educational Counseling for POD</arm_group_label>
    <arm_group_label>Physician Management</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Educational Counseling</intervention_name>
    <description>Didactic, lecture-discussion format to supplement information and advice provided by physicians</description>
    <arm_group_label>Educational Counseling for POD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physician Management</intervention_name>
    <description>Brief physician counseling</description>
    <arm_group_label>Physician Management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  prescription opioid addiction criteria&#xD;
&#xD;
          -  moderate to severe chronic pain&#xD;
&#xD;
          -  seeking or interested in buprenorphine maintenance&#xD;
&#xD;
          -  understand English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  methadone maintenance at a dose greater than 40 mg daily&#xD;
&#xD;
          -  current suicide or homicide risk&#xD;
&#xD;
          -  life-threatening or unstable medical problem&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard S Schottenfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Methadone Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 2, 2008</study_first_submitted>
  <study_first_submitted_qc>March 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2008</study_first_posted>
  <results_first_submitted>August 16, 2020</results_first_submitted>
  <results_first_submitted_qc>August 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 1, 2020</results_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CBT for POD</title>
          <description>Integrated cognitive behavioral therapy for chronic pain and opioid dependence&#xD;
CBT: Cognitive behavioral therapy&#xD;
Buprenorphine: buprenorphine/naloxone</description>
        </group>
        <group group_id="P2">
          <title>Educational Counseling for POD</title>
          <description>Educational Counseling is a didactic, lecture-discussion format to supplement the information and advice provided by physicians in physician management (PM)&#xD;
Buprenorphine: buprenorphine/naloxone&#xD;
Educational Counseling: Didactic, lecture-discussion format to supplement information and advice provided by physicians</description>
        </group>
        <group group_id="P3">
          <title>Physician Management</title>
          <description>PM is a relatively brief intervention that approximates the medically focused advice and brief counseling about medical issues that is typically provided by physicians to patients with chronic pain or other chronic medical conditions, such as diabetes or asthma.&#xD;
Buprenorphine: buprenorphine/naloxone&#xD;
Physician Management: Brief physician counseling</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Month 1</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Month 2</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Month 3</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CBT for POD</title>
          <description>Integrated cognitive behavioral therapy for chronic pain and opioid dependence&#xD;
CBT: Cognitive behavioral therapy&#xD;
Buprenorphine: buprenorphine/naloxone</description>
        </group>
        <group group_id="B2">
          <title>Educational Counseling for POD</title>
          <description>Educational Counseling is a didactic, lecture-discussion format to supplement the information and advice provided by physicians in physician management (PM)&#xD;
Buprenorphine: buprenorphine/naloxone&#xD;
Educational Counseling: Didactic, lecture-discussion format to supplement information and advice provided by physicians</description>
        </group>
        <group group_id="B3">
          <title>Physician Management</title>
          <description>PM is a relatively brief intervention that approximates the medically focused advice and brief counseling about medical issues that is typically provided by physicians to patients with chronic pain or other chronic medical conditions, such as diabetes or asthma.&#xD;
Buprenorphine: buprenorphine/naloxone&#xD;
Physician Management: Brief physician counseling</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.3" spread="9.4"/>
                    <measurement group_id="B2" value="37.0" spread="9.9"/>
                    <measurement group_id="B3" value="35.3" spread="10.00"/>
                    <measurement group_id="B4" value="35.8" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity</title>
        <description>Pain intensity comprises the average of 4 items related to current pain and past-week average pain, pain at its worst, and pain at its least. Pain intensity is scored on 0-10 scale (average score ranges from 0-10), where higher scores indicate higher pain intensity.Originally labeled as Pain Reduction at 16 weeks- 3 months was the correct timeframe.</description>
        <time_frame>3 months</time_frame>
        <population>The analysis population is the intention to treat population and all observations across time periods were used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CBT for POD</title>
            <description>Integrated cognitive behavioral therapy for chronic pain and opioid dependence&#xD;
CBT: Cognitive behavioral therapy&#xD;
Buprenorphine: buprenorphine/naloxone</description>
          </group>
          <group group_id="O2">
            <title>Educational Counseling for POD</title>
            <description>Educational Counseling is a didactic, lecture-discussion format to supplement the information and advice provided by physicians in physician management (PM)&#xD;
Buprenorphine: buprenorphine/naloxone&#xD;
Educational Counseling: Didactic, lecture-discussion format to supplement information and advice provided by physicians</description>
          </group>
          <group group_id="O3">
            <title>Physician Management</title>
            <description>PM is a relatively brief intervention that approximates the medically focused advice and brief counseling about medical issues that is typically provided by physicians to patients with chronic pain or other chronic medical conditions, such as diabetes or asthma.&#xD;
Buprenorphine: buprenorphine/naloxone&#xD;
Physician Management: Brief physician counseling</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity</title>
          <description>Pain intensity comprises the average of 4 items related to current pain and past-week average pain, pain at its worst, and pain at its least. Pain intensity is scored on 0-10 scale (average score ranges from 0-10), where higher scores indicate higher pain intensity.Originally labeled as Pain Reduction at 16 weeks- 3 months was the correct timeframe.</description>
          <population>The analysis population is the intention to treat population and all observations across time periods were used in the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intake/Induction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.43" spread="1.34"/>
                    <measurement group_id="O2" value="5.92" spread="1.57"/>
                    <measurement group_id="O3" value="5.28" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.75" spread="1.62"/>
                    <measurement group_id="O2" value="5.02" spread="1.45"/>
                    <measurement group_id="O3" value="4.53" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.79" spread="1.50"/>
                    <measurement group_id="O2" value="4.98" spread="1.76"/>
                    <measurement group_id="O3" value="4.72" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.41" spread="1.67"/>
                    <measurement group_id="O2" value="4.62" spread="1.91"/>
                    <measurement group_id="O3" value="4.84" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Opioid-negative Urine Toxicology Tests</title>
        <description>Reduced illicit opioid use is defined as the number of documented opioid negative urine tests in each of the time periods.This measures the reduction in illicit opioid use - more opioid-negative tests means greater reductions in illicit opioid use. The highest possible score is 4- which would indicate 4 negative urine tests during the assessment period. Originally titled &quot;Reduced illicit opioid use&quot; and the timeframe was listed as 16 weeks.</description>
        <time_frame>3 Months</time_frame>
        <population>The analysis population is the intention to treat population and all observations across time periods were used in the analysis. Participants may have contributed to this outcome but were lost to follow up during the time period and were not measured on pain related outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>CBT for POD</title>
            <description>Integrated cognitive behavioral therapy for chronic pain and opioid dependence&#xD;
CBT: Cognitive behavioral therapy&#xD;
Buprenorphine: buprenorphine/naloxone</description>
          </group>
          <group group_id="O2">
            <title>Educational Counseling for POD</title>
            <description>Educational Counseling is a didactic, lecture-discussion format to supplement the information and advice provided by physicians in physician management (PM)&#xD;
Buprenorphine: buprenorphine/naloxone&#xD;
Educational Counseling: Didactic, lecture-discussion format to supplement information and advice provided by physicians</description>
          </group>
          <group group_id="O3">
            <title>Physician Management</title>
            <description>PM is a relatively brief intervention that approximates the medically focused advice and brief counseling about medical issues that is typically provided by physicians to patients with chronic pain or other chronic medical conditions, such as diabetes or asthma.&#xD;
Buprenorphine: buprenorphine/naloxone&#xD;
Physician Management: Brief physician counseling</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Opioid-negative Urine Toxicology Tests</title>
          <description>Reduced illicit opioid use is defined as the number of documented opioid negative urine tests in each of the time periods.This measures the reduction in illicit opioid use - more opioid-negative tests means greater reductions in illicit opioid use. The highest possible score is 4- which would indicate 4 negative urine tests during the assessment period. Originally titled &quot;Reduced illicit opioid use&quot; and the timeframe was listed as 16 weeks.</description>
          <population>The analysis population is the intention to treat population and all observations across time periods were used in the analysis. Participants may have contributed to this outcome but were lost to follow up during the time period and were not measured on pain related outcomes.</population>
          <units>opioid negative urine tests</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intake/Induction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.55"/>
                    <measurement group_id="O2" value="0.67" spread="0.48"/>
                    <measurement group_id="O3" value="0.55" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" spread="1.42"/>
                    <measurement group_id="O2" value="2.80" spread="1.27"/>
                    <measurement group_id="O3" value="2.48" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" spread="1.48"/>
                    <measurement group_id="O2" value="3.30" spread="1.14"/>
                    <measurement group_id="O3" value="2.56" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.80" spread="1.38"/>
                    <measurement group_id="O2" value="3.25" spread="1.22"/>
                    <measurement group_id="O3" value="2.04" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Interference</title>
        <description>Pain interference comprises the average of 7 items related to past-week pain-related interference in general activity, walking, work, mood, enjoyment of life, relations with others, and sleep. Each item is scored on a 0-10 scale (averaged 0-10), where higher scores indicate higher pain interference.</description>
        <time_frame>3 Months</time_frame>
        <population>The analysis population is the intention to treat population and all observations across time periods were used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CBT for POD</title>
            <description>Integrated cognitive behavioral therapy for chronic pain and opioid dependence&#xD;
CBT: Cognitive behavioral therapy&#xD;
Buprenorphine: buprenorphine/naloxone</description>
          </group>
          <group group_id="O2">
            <title>Educational Counseling for POD</title>
            <description>Educational Counseling is a didactic, lecture-discussion format to supplement the information and advice provided by physicians in physician management (PM)&#xD;
Buprenorphine: buprenorphine/naloxone&#xD;
Educational Counseling: Didactic, lecture-discussion format to supplement information and advice provided by physicians</description>
          </group>
          <group group_id="O3">
            <title>Physician Management</title>
            <description>PM is a relatively brief intervention that approximates the medically focused advice and brief counseling about medical issues that is typically provided by physicians to patients with chronic pain or other chronic medical conditions, such as diabetes or asthma.&#xD;
Buprenorphine: buprenorphine/naloxone&#xD;
Physician Management: Brief physician counseling</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Interference</title>
          <description>Pain interference comprises the average of 7 items related to past-week pain-related interference in general activity, walking, work, mood, enjoyment of life, relations with others, and sleep. Each item is scored on a 0-10 scale (averaged 0-10), where higher scores indicate higher pain interference.</description>
          <population>The analysis population is the intention to treat population and all observations across time periods were used in the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intake/Induction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.75" spread="2.12"/>
                    <measurement group_id="O2" value="5.48" spread="2.23"/>
                    <measurement group_id="O3" value="5.01" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15" spread="2.09"/>
                    <measurement group_id="O2" value="3.74" spread="1.82"/>
                    <measurement group_id="O3" value="3.32" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.08" spread="2.06"/>
                    <measurement group_id="O2" value="3.61" spread="1.97"/>
                    <measurement group_id="O3" value="3.45" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.22" spread="1.94"/>
                    <measurement group_id="O2" value="3.23" spread="2.27"/>
                    <measurement group_id="O3" value="3.87" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to the end of study (month 3)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CBT for POD</title>
          <description>Integrated cognitive behavioral therapy for chronic pain and opioid dependence&#xD;
CBT: Cognitive behavioral therapy&#xD;
Buprenorphine: buprenorphine/naloxone</description>
        </group>
        <group group_id="E2">
          <title>Educational Counseling for POD</title>
          <description>Educational Counseling is a didactic, lecture-discussion format to supplement the information and advice provided by physicians in physician management (PM)&#xD;
Buprenorphine: buprenorphine/naloxone&#xD;
Educational Counseling: Didactic, lecture-discussion format to supplement information and advice provided by physicians</description>
        </group>
        <group group_id="E3">
          <title>Physician Management</title>
          <description>PM is a relatively brief intervention that approximates the medically focused advice and brief counseling about medical issues that is typically provided by physicians to patients with chronic pain or other chronic medical conditions, such as diabetes or asthma.&#xD;
Buprenorphine: buprenorphine/naloxone&#xD;
Physician Management: Brief physician counseling</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard S. Schottenfeld, M.D.</name_or_title>
      <organization>Yale University</organization>
      <phone>203-974-7349</phone>
      <email>richard.schottenfeld@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

